Education
About Us
Working with TipRanks
Follow Us
Sartorius Stedim Biotech (GB:0RG8)
LSE:0RG8
RESEARCH TOOLSreports
Total Valuation
Sartorius Stedim Biotech has a market cap or net worth of €17.02B. The enterprise value is €22.04B.
Market Cap€17.02B
Enterprise Value€22.04B
Share Statistics
Sartorius Stedim Biotech has 97,330,410 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding97,330,410
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Sartorius Stedim Biotech’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 4.09%.
Return on Equity (ROE)0.04
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)4.09%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee279.09K
Profits Per Employee22.01K
Employee Count9,961
Asset Turnover0.34
Inventory Turnover2.30
Valuation Ratios
The current PE Ratio of Sartorius Stedim Biotech is 76.8. Sartorius Stedim Biotech’s PEG ratio is -2.26.
PE Ratio76.8
PS Ratio6.57
PB Ratio4.58
Price to Fair Value4.58
Price to FCF38.42
Price to Operating Cash Flow21.40
PEG Ratio-2.26
Income Statement
In the last 12 months, Sartorius Stedim Biotech had revenue of 2.78B and earned 175.10M in profits. Earnings per share was 1.81.
Revenue2.78B
Gross Profit1.21B
Operating Income370.60M
Pretax Income219.20M
Net Income175.10M
EBITDA670.50M
Earnings Per Share (EPS)1.81
Cash Flow
In the last 12 months, operating cash flow was 788.10M and capital expenditures -291.60M, giving a free cash flow of 496.50M billion.
Operating Cash Flow788.10M
Free Cash Flow496.50M
Free Cash Flow per Share5.10
Dividends & Yields
Sartorius Stedim Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.79
52-Week Price Change-2.57%
50-Day Moving Average187.06
200-Day Moving Average191.81
Relative Strength Index (RSI)43.80
Average Volume (3m)9.91K
Important Dates
Sartorius Stedim Biotech upcoming earnings date is Oct 16, 2025, Before Open (Confirmed).
Last Earnings DateJul 22, 2025
Next Earnings DateOct 16, 2025
Ex-Dividend Date―
Financial Position
Sartorius Stedim Biotech as a current ratio of 1.85, with Debt / Equity ratio of 74.17%
Current Ratio1.85
Quick Ratio1.12
Debt to Market Cap0.15
Net Debt to EBITDA3.27
Interest Coverage Ratio2.33
Taxes
In the past 12 months, Sartorius Stedim Biotech has paid 40.70M in taxes.
Income Tax40.70M
Effective Tax Rate0.19
Enterprise Valuation
Sartorius Stedim Biotech EV to EBITDA ratio is 30.50, with an EV/FCF ratio of 43.03.
EV to Sales7.36
EV to EBITDA30.50
EV to Free Cash Flow43.03
EV to Operating Cash Flow25.09
Balance Sheet
Sartorius Stedim Biotech has €745.10M in cash and marketable securities with €2.97B in debt, giving a net cash position of €2.22B billion.
Cash & Marketable Securities€745.10M
Total Debt€2.97B
Net Cash€2.22B
Net Cash Per Share€22.85
Tangible Book Value Per Share-€5.33
Margins
Gross margin is 44.63%, with operating margin of 13.33%, and net profit margin of 6.30%.
Gross Margin44.63%
Operating Margin13.33%
Pretax Margin7.88%
Net Profit Margin6.30%
EBITDA Margin24.12%
EBIT Margin13.27%
Analyst Forecast
The average price target for Sartorius Stedim Biotech is €227.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€227.38
Price Target Upside29.30% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast―